Richard C. Yocum

Bexarotene Is Effective and Safe for Treatment of Refractory Advanced-Stage Cutaneous T-Cell Lymphoma: Multinational Phase II-III Trial Results

Madeleine Duvic, Kenneth B. Hymes, Peter Heald et al. · Journal of Clinical Oncology · 2001 · 701 citations

Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma.

Madeleine Duvic, Ángel G. Martín, Y. Kim et al. · PubMed · 2001 · 437 citations

Phase 1 and 2 Trial of Bexarotene Gel for Skin-Directed Treatment of Patients With Cutaneous T-Cell Lymphoma

Debra Breneman, Madeleine Duvic, Timothy M. Kuzel et al. · Archives of Dermatology · 2002 · 209 citations

Immunology, Bexarotene Gel, Pharmacotherapy +16

Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial

Peter Heald, Marilyn A. Mehlmauer, Ann Martin et al. · Journal of the American Academy of Dermatology · 2003 · 159 citations

Lymphoid Neoplasia, Topical Bexarotene Therapy, Medicine +5

Multicenter Phase II Study of Oral Bexarotene for Patients With Metastatic Breast Cancer

Francisco J. Esteva, John A. Glaspy, Said Baidas et al. · Journal of Clinical Oncology · 2003 · 116 citations